Bionomics, an Australian biotechnology company, said it acquired Eclipse Therapeutics, a San Diego-based biotechnology company, in a $10 million deal.
Eclipse Therapeutics, which was spun off from Biogen Idec, is developing drug candidates that target cancer stem cells.
“This acquisition elevates and expands Bionomics' oncology pipeline beyond BNC105, our primary cancer drug candidate, which is now at advanced clinical stages,” Bionomics CEO and Managing Director Dr. Deborah Rathjen (PDF) said in a news release. “It also establishes Bionomics as a global leader at the forefront of cancer stem-cell therapeutics.
